Long-term outcomes of patients with Waldenström's macroglobulinemia who discontinue BTKi therapy
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-06-26
Просмотров: 640
Описание:
Karan Chohan, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an analysis of the long-term outcomes of patients with Waldenström's macroglobulinemia (WM) who discontinue BTK inhibitor (BTKi) therapy. Dr Chohan highlights that among patients who discontinued BTKi therapy, those who did so due to disease progression or transformation had equivalent outcomes with subsequent treatments. He also notes that in patients discontinuing BTKi therapy due to adverse events or other reasons, it is possible to consider using a different BTKi-based therapy. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
